Navigation Links
Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors
Date:10/16/2009

NEW YORK, Oct. 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors

http://www.reportlinker.com/p0154665/Reportlinker-Adds-Competitor-Analysis-PI3K-AKT-mTOR-Inhibitors.html

Product description

The present Competitive Intelligence Report about PI3K-AKT-mTOR Inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting members of the phosphatidyl-inositol-3 kinase (PI3K) / Akt / mammalian target of rapamycin (mTOR) pathway for treatment of cancer or inflammatory diseases as of July 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in the regulation of cellular growth, survival, and proliferation. Dysregulation of this pathway, as a result of genetic mutations and amplifications, is implicated in a variety of human cancers. Therefore, each of the three components of the pathway alone and in combination has emerged as a key target for the treatment of cancer. While first generation therapeutic agents currently in clinical evaluation preferably are pan-PI3K inhibitors, next generation selective PI3K inhibitors are targeting one or several different subclasses.

However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiologic signaling. Since that time, studies have delineated the roles of these four isoforms in nonpathologic signaling as well as their roles in cancer. An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, e.g. alpha and beta, as well as closely related proteins implicated in cancer. These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a number are in clinical testing.

Numerous components of the PI3K pathway play an important role in the expression and activation of inflammatory mediators, inflammatory cell recruitment, immune cell function, airway remodelling and corticosteroid insensitivity in asthma. More recently studies exploring the specific roles of different PI3K catalytic subunit isoforms in asthma have been initiated. Several of these have highlighted the importance of the delta isoform as a novel target for therapeutic intervention in asthma.

Two mTOR complexes have been characterized, termed mTORC1 (mTOR complex-1) and mTORC2. mTORC1 phosphorylates the hydrophobic motif of S6K, whereas mTORC2 phosphorylates the hydrophobic motif of Akt and SGK. The central role of mTOR in controlling key cellular growth and survival pathways has sparked interest in discovering mTOR inhibitors that bind to the ATP site and therefore target both mTORC2 and mTORC1 (mTORC2 is resistant to rapamycin).

The report includes a compilation of current active projects in research and development of PI3K-AKT-mTOR inhibitors in oncology and other indications. In addition, the report lists company-specific R&D pipelines of PI3K-AKT-mTOR inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Index

  • Selective PI3K Inhibitors in Oncology Indications
  • Selective PI3K Inhibitors in Inflammatory and Other Indications
  • Non-Specific PI3K Inhibitors in Oncology Indications
  • Dual PI3K/mTOR Inhibitors
  • Selective mTOR Inhibitors in Oncology Indications
  • Selective mTOR Inhibitors in Inflammatory and Other Indications
  • Selective AKT Inhibitors in Oncology Indications
  • AKT Dual Pathway Inhibitors in Oncology Indications
  • Non-Specific AKT Inhibitors in Oncology Indications
  • Corporate PI3K-AKT-mTOR Inhibitor R&D Pipelines
  • About La Merie

Corporate PI3K-AKT-mTOR Inhibitor R&D Pipelines

  • Abbott
  • Abraxis Biosciences
  • Aeterna Zentaris
  • Ariad Pharmaceuticals
  • Arno Therapeutics
  • Astex Pharmaceuticals
  • AstraZeneca
  • Bayer Schering Pharma
  • Biotica
  • Calistoga Pharmaceuticals
  • Cellzome
  • CompleGen
  • Eli Lilly
  • Enzon Pharmaceuticals
  • Exelixis
  • Genentech
  • GlaxoSmithKline (GSK)
  • ICON
  • Intellikine
  • Isotechnika
  • Keryx Biopharmaceuticals
  • MacuSight
  • Merck
  • Novartis
  • Oncothyreon
  • OSI Pharmaceuticals
  • Pfizer
  • Piramal Life Sciences
  • Roche
  • S*Bio
  • Samtheo Biopharma
  • Sanofi-aventis
  • Santen Pharmaceutical
  • Semafore Pharmaceuticals
  • SRI International
  • Teva Pharmaceutical
  • TopoTarget
  • VioQuest Pharmaceuticals
  • Wilex
  • Wyeth
  • Xcovery
  • Zenyaku Kogyo

To order this report:

Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors

http://www.reportlinker.com/p0154665/Reportlinker-Adds-Competitor-Analysis-PI3K-AKT-mTOR-Inhibitors.html

More market research reports here!

    Contact: Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile
2. Reportlinker Adds Allergan Inc.: PharmaVitae Profile
3. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
4. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
5. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
6. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
9. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
10. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
11. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... N.Y. , Feb. 5, 2016  Henry Schein, ... health care products and services to office-based dental, animal ... entered into an agreement to acquire a majority ownership ... supplies and equipment in Brazil . ... Headquartered in Blumenau, Brazil, Dental Cremer is the dental distribution ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
(Date:2/4/2016)... 4, 2016   Bernstein Liebhard LLP today announced ... United States District Court for the District of ... consisting of all persons or entities who purchased common shares ... INSY ) from March 3, 2015 through January 25, 2016 ... its officers with violations of the Securities Exchange Act of ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... US Sports Camps , official operators of Nike ... high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New ... ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Calls Blacklist has ... completely new user interface design and the developer has fixed known bugs within the ... want to on their phone while not consuming any of their device’s battery power ...
Breaking Medicine News(10 mins):